XiaojinAn Ph.D.


Beijing + 86.10.5866.1130 Munich +

Xiaojin An focuses her practice on obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics. She has extensive experience in antibodies, peptides, vaccines, stem cells, immune therapies, diagnostic methods, gene editing, and personalized medicine.

Xiaojin represents clients in patent proceedings before the European Patent Office, including drafting, prosecution, opposition, and appeal. She also has experience in national invalidity and infringement proceedings. Xiaojin advises clients on opposing and defending patents, freedom-to-operate, patent life cycle management, and supplementary protection certificates (SPCs). In addition to managing global patent portfolios, Xiaojin conducts IP due diligence in connection with merger, acquisition, and license agreements.

Prior to joining Jones Day in 2013, Xiaojin was a postdoctoral fellow at the Swiss Federal Institute of Technology Zurich (ETH), where her research focused on profiling circulating microRNA biomarkers for cancer and identification of metabolic addiction pathways for cancer cell survival. Xiaojin carried out her Ph.D. studies at Harvard Medical School and Peking University. She received an outstanding doctoral dissertation award for her work on angiogenesis in cancer and cardiovascular disease, focusing on gene regulation in hypoxic endothelium. Xiaojin has published eight research articles and reviews in peer-reviewed top journals.


  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Speaking Engagements

    • September 25, 2019
      Maximizing protection for your key therapeutic product in Europe.